Status:
COMPLETED
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-85 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of Exelon® patch in patients with probable AD (MMSE 10-20), in order to support a planned regulatory submission and regist...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- have a diagnosis of dementia of the Alzheimer's type according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria;
- have a clinical diagnosis of probable AD according to NINCDS/ADRDA criteria.
- have a brain scan (magnetic resonance imaging (MRI) or computed tomography (CT)) consistent with the diagnosis of AD. The brain scan must have been performed within one year prior to randomization;
- have an MMSE score of ≥ 10 and ≤ 20;
- have sufficient education to have been able to read, write, and communicate effectively during the premorbid state;
- be residing with someone in the community throughout the study or, if living alone, in contact with the primary caregiver everyday;
- Exclusion criteria:
- have an advanced, severe, progressive, or unstable infectious, metabolic, immune, endocrinologic, hepatic, hematological, pulmonary, cardiovascular, gastrointestinal, and/or urological condition that may interfere with efficacy and safety assessments or put the patient at special risk;
- have a history or current diagnosis of any medical or neurological condition other than AD that is identified as contributing cause of the patient's dementia;
- have a current diagnosis of probable or possible vascular dementia according to the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences criteria (NINDS-AIREN);
- have a score of \> 4 on the Modified Hachinski Ischemic Scale (MHIS);
- have a current DSM-IV diagnosis of major depression, unless, in the opinion of the investigator, is in remission for at least 12 weeks;
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
501 Patients enrolled
Trial Details
Trial ID
NCT01399125
Start Date
July 1 2011
End Date
May 1 2013
Last Update
August 4 2014
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Fuzhou, Fujian, China
2
Novartis Investigative Site
Wuhan, Hubei, China, 430022
3
Novartis Investigative Site
Wuhan, Hubei, China, 430030
4
Novartis Investigative Site
Nanjing, Jiangsu, China, 210029